Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche Boasts Of Tecentriq's Broad Potential In 3Q Earnings Update

Roche CEO Severin Schwan called recently launched PD-L1 drug Tecentriq's CHF77m sales figure impressive when presenting the company's third-quarter earnings on Oct. 20. Roche also spotlighted its "comprehensive" immuno-oncology portfolio which is producing "quantity as well as quality" with five product launches in 12 months.

Financial Reports Companies Cancer

Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity

New treatments for atopic dermatitis – including the first biologic medicine for the disease – could launch next year, fueling substantial growth in a therapy area where there have been few advances. Payers, however, will be keeping an eye on the cost.

Market Intelligence Dermatology Product Launch

ICER Atopic Dermatitis Review Prompted By First Biologic

The Institute for Clinical and Economic Review’s assessment of emerging therapies for atopic dermatitis was driven by both excitement and concern from physicians and payers over the anticipated launch of Regeneron/Sanofi’s dupilumab.

BioPharmaceutical Dermatology Commercial

Will Japan Pharma Fall In Line With R&D Externalization Trends?

Japanese pharma companies are generally following the same trends as their global counterparts when it comes to the externalization of R&D, and revenues from internal projects are set to fall over the next few years, with Takeda in particular expected to look much more to external opportunities.

Japan Research and Development Strategies Clinical R and D

 Recent Tweets from Scrip

Commercial Explore this Topic

AbbVie Knocks Back Ablynx's Vobarilizumab In RA

A major setback for Ablynx as AbbVie decides not to exercise its opt-in for vobarilizumab in rheumatoid arthritis. Though the competitive landscape of biologics targeting IL-6 casts a shadow over its commercial prospects, Ablynx is determined to continue development.

Companies Commercial Inflammation

Modus's Intended IPO to Spur Sickle Cell Drug R&D

The first IPO for a pharmaceutical company nurtured by Karolinska Development is expected to involve Modus Therapeutics, which has changed its name from Dilaforette and is pursuing the development of a Phase II potential sickle cell therapy.

Financing Clinical R and D Incubators

Latest From Commercial

Asia On The Move: Flurry Of Japan Appointments, Changes

The start of the fiscal second half in Japan in October brought a flurry of executive changes and reorganizations at foreign and domestic firms in the country including Allergan, Sandoz and Takeda.

People Japan

China Precision Medicine Push Boosting Genomic Business Forays

As the traditional lines between therapeutics and diagnostics become increasingly blurred, genomic testing is growing apace in China, boosted by the country’s national push into precision medicine. Deals and alliances are coming thick and fast as companies jostle for a slice of the growing pie.

China Business Strategies

Pfizer Assembling New Commercial Team For Move Into Dermatology

The big pharma is moving into a new therapy area – dermatology – as part of a three-pronged strategy in Inflammation & Immunology that also includes rheumatology and gastroenterology. Pfizer’s first product for dermatology, crisaborole for atopic dermatitis, could launch next year.

Dermatology Inflammation

Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks

Kite plans to initially target 72 clinical institutions experienced with CAR-T for its KTE-C19 launch, including 10 from the get-go.

Cancer Clinical Trials

Sinovac Take-Private Deal Facing Challenges

Sinovac’s lengthy take-private process could be further delayed by the cloudy outlook for a potential relisting in China due to regulatory uncertainty and a tougher domestic environment, although the Chinese company’s rising competitiveness in the domestic vaccines market should help increase its valuation.

Financing China

Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira

Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.

Biosimilars Companies

Policy & Regulation Explore this Topic

NICE OK For BMS's Opdivo To Shake Up UK RCC Market, Bad News For Pfizer

Bristol-Myers Squibb's Opdivo looks set to blow rivals out the water in renal cell carcinoma as NICE U-turns on negative recommendation, just weeks after the company revealed the full extent of the drug’s disappointment in first-line lung cancer.

Health Technology Assessment Commercial Cancer

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Genentech’s PD-L1 inhibitor Tecentriq could steal market share from the PD-1 inhibitors Opdivo and Keytruda in its new indication, but the Roche subsidiary’s drug is a year behind competitors from Bristol-Myers and Merck in NSCLC with seven Phase III trials under way to expand its reach in lung cancer.

Policy and Regulation Commercial Approvals

Latest From Policy and Regulation

US Treasury’s Final Earnings Stripping Guidance Keeps Pressure On Inversions

The US Treasury released final guidance to eliminate one of the economic motivations behind inversion deals, the threat of which in April derailed the Pfizer/Allergan mega merger. It doesn’t, however, affect other practices as feared.

Business Strategies US Election 2016

From Solanezumab To Solithromycin: What To Watch For In Q4

Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.

Clinical R and D Policy and Regulation

Investors Relieved As Mylan Settlement Avoids Investigation

Mylan shares rallied on Oct. 7 following the company’s late-day Oct. 10 announcement that it agreed to settlement terms with the Department of Justice related to Epipen rebates for Medicaid prescriptions, but separate investigations and competition are looming.

Commercial Companies

More M&A, Expertise, Data Seen As Key To Korea Pharma Potential

Participants at a recent conference in Seoul called for more steps to nurture original R&D, encourage M&A, attract foreign investment, develop industry expertise, and create new resources on global markets and potential partners if South Korea’s pharma sector is to emerge as a global powerhouse.

South Korea Policy and Regulation

Industry Proposes New Pharma Support Roadmap For Turkey

In a new report, the Turkish research-based pharma industry association the AIFD is calling on the government to improve the investment environment for the sector and to take steps including tax reductions to encourage R&D, innovation and manufacturing investment.

Turkey Policy and Regulation

Bridging The Drug Price Divide: Ideas And Approaches Debated At PSA

Leaders from across the industry met at Informa's Pharmaceutical Strategy conference and addressed some of the most critical issues facing the industry: pharma's tarnished reputation and drug pricing.

Pricing Debate Business Strategies

Clinical / R&D Explore this Topic

PIPELINE WATCH: Progress In Lung And Prostate Cancer, But Interferon Disappoints In Asthma

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Clinical R and D BioPharmaceutical

J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster sales. J&J adds that it’s planning 40 line extensions, with 10 that could yield $500m annually each.

Sales and Earnings Cancer Business Strategies

Latest From Clinical R and D

Sun Dips Toe Into Vaccines With Dengvaxia Challenge

India's top-ranked drug firm Sun Pharma is vying for a play in the dengue vaccines space via a collaboration with the non-profit research organization, International Centre for Genetic Engineering and Biotechnology. The partners expect their vaccine candidate to potentially best live-attenuated dengue vaccine candidates, including Sanofi's Dengvaxia.

Clinical R and D Strategy

Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class

One case of adjudicated arthropathy seen in halted Phase IIb study of anti-NGF candidate. Regeneron still hopes to advance fasinumab, partnered with Teva, into Phase III in osteoarthritis and chronic low back pain – but the second clinical hold for the class puts its future into even greater question.

Drug Safety Clinical Trials

Efficiency Bows To Scrutiny: '90s Drug Development Timelines Have Doubled

The time it takes to get a new drug candidate through clinical trials and onto the market has almost doubled since the late 1990s – but timescales for discovering new drug candidates haven't changed over the past 15 years.

Clinical R and D Preclinical Through Proof Of Concept

Intercept's Ocaliva Eyes Vacant Ground In Europe

Intercept is gearing for launch in Europe following the CHMP's positive opinion for Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis, an indication for which there is currently only one approved medication in Europe.

Approvals Clinical R and D

Profile: GSK's David Leather On Transitioning from GP And Radio Doctor to Real World Evidence Tsar

David Leather – the man behind GlaxoSmithKline's ground-breaking real-world evidence initiative, the Salford Lung Study – is GSK’s in-house real world evidence expert. He spoke with Scrip about his transition from the National Health Service to industry, what it was like to set up Viiv with Pfizer and the future of RWE.

Clinical R and D Market Access

Phase III Boost For Esperion But Does It Own Its Destiny?

Esperion will be allowed to enroll patients on high dose statins into the Phase III pivotal trial of its cholesterol lowering drug bempedoic acid, but with competing products ahead in the race, the product faces an uphill battle for market share even if it does garner approval.

Clinical R and D Cardiovascular